Aggressives B-Zell-Non-Hodgkin-Lymphom der Mamma bei einer 77-jährigen Patientin

Fabian Riedel; L. Sellner; A. Harcos; H. P. Sinn; A. Hennigs; M. Golatta; J. Heil; L. Mayer

doi:10.1055/a-0583-8601

TumorDiagnostik & Therapie, Table of Contents

TumorDiagnostik & Therapie 2018; 39(04): 239-242
DOI: 10.1055/a-0583-8601

Thieme Onkologie aktuell

Aggressives B-Zell-Non-Hodgkin-Lymphom der Mamma bei einer 77-jährigen Patientin

Fabian Riedel

¹Universitätsklinikum Heidelberg, Frauenklinik

,

L. Sellner

²Universitätsklinikum Heidelberg, Medizinische Klinik V

,

A. Harcos

¹Universitätsklinikum Heidelberg, Frauenklinik

,

H. P. Sinn

³Universitätsklinikum Heidelberg, Pathologisches Institut

,

A. Hennigs

¹Universitätsklinikum Heidelberg, Frauenklinik

,

M. Golatta

¹Universitätsklinikum Heidelberg, Frauenklinik

,

J. Heil

¹Universitätsklinikum Heidelberg, Frauenklinik

,

L. Mayer

¹Universitätsklinikum Heidelberg, Frauenklinik

› Author Affiliations

Abstract

Full Text

References

Literatur
1 Sabate JM, Gomez A, Torrubia S. et al. Lymphoma of the breast: clinical and radiologic features with pathologic correlation in 28 patients. The breast journal 2002; 8: 294-304
2 Thomas A, Link BK, Altekruse S. et al. Primary Breast Lymphoma in the United States: 1975–2013. Journal of the National Cancer Institute 2017; 109: djw294
3 Doren EL, Miranda RN, Selber JC. et al. U.S. Epidemiology of Breast Implant-Associated Anaplastic Large Cell Lymphoma. Plastic and reconstructive surgery 2017; 139: 1042-1050
4 Surov A, Holzhausen HJ, Wienke A. et al. Primary and secondary breast lymphoma: prevalence, clinical signs and radiological features. The British journal of radiology 2012; 85: e195-e205
5 Yang WT, Lane DL, Le-Petross HT. et al. Breast lymphoma: imaging findings of 32 tumors in 27 patients. Radiology 2007; 245: 692-702
6 Kim Y, Ko KH, Jung HK. et al. Shear-Wave Elastography Features of Primary Non-Hodgkinʼs Lymphoma of the Breast: A Case Report and Literature Review. Journal of clinical and diagnostic research: JCDR 2016; 10: Td01-Td03
7 Martinelli G, Ryan G, Seymour JF. et al. Primary follicular and marginal-zone lymphoma of the breast: clinical features, prognostic factors and outcome: a study by the International Extranodal Lymphoma Study Group. Annals of oncology: official journal of the European Society for Medical Oncology/ESMO 2009; 20: 1993-1999
8 Validire P, Capovilla M, Asselain B. et al. Primary breast non-Hodgkinʼs lymphoma: a large single center study of initial characteristics, natural history, and prognostic factors. American journal of hematology 2009; 84: 133-139
9 Yhim HY, Kang HJ, Choi YH. et al. Clinical outcomes and prognostic factors in patients with breast diffuse large B cell lymphoma; Consortium for Improving Survival of Lymphoma (CISL) study. BMC cancer 2010; 10: 321
10 Aviv A, Tadmor T, Polliack A. Primary diffuse large B-cell lymphoma of the breast: looking at pathogenesis, clinical issues and therapeutic options. Annals of oncology: official journal of the European Society for Medical Oncology/ESMO 2013; 24: 2236-2244
11 Sun Y, Joks M, Xu LM. et al. Diffuse large B-cell lymphoma of the breast: prognostic factors and treatment outcomes. OncoTargets and therapy 2016; 9: 2069-2080
12 Franco Perez F, Lavernia J, Aguiar-Bujanda D. et al. Primary Breast Lymphoma: Analysis of 55 Cases of the Spanish Lymphoma Oncology Group. Clinical lymphoma, myeloma & leukemia 2017; 17: 186-191
13 Lister TA, Crowther D, Sutcliffe SB. et al. Report of a committee convened to discuss the evaluation and staging of patients with Hodgkinʼs disease: Cotswolds meeting. Journal of clinical oncology: official journal of the American Society of Clinical Oncology 1989; 7: 1630-1636
14 Cunningham D, Hawkes EA, Jack A. et al. Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles. Lancet 2013; 381: 1817-1826
15 Kuhnl A, Cunningham D, Counsell N. et al. Outcome of Elderly Patients with Diffuse Large B-cell Lymphoma Treated with R-CHOP: Results from the UK NCRI R-CHOP14v21 trial with combined analysis of molecular characteristics with the DSHNHL RICOVER-60 trial. Annals of oncology: official journal of the European Society for Medical Oncology/ESMO 2017;
16 Schmitz N, Zeynalova S, Nickelsen M. et al. CNS International Prognostic Index: A Risk Model for CNS Relapse in Patients With Diffuse Large B-Cell Lymphoma Treated With R-CHOP. Journal of clinical oncology: official journal of the American Society of Clinical Oncology 2016; 34: 3150-3156
17 Abramson JS, Hellmann M, Barnes JA. et al. Intravenous methotrexate as central nervous system (CNS) prophylaxis is associated with a low risk of CNS recurrence in high-risk patients with diffuse large B-cell lymphoma. Cancer 2010; 116: 4283-4290
18 Bicchierai G, Rigacci L, Miele V. et al. Role of core needle biopsy in primary breast lymphoma. La Radiologia medica 2017;
19 Uesato M, Miyazawa Y, Gunji Y. et al. Primary non-Hodgkinʼs lymphoma of the breast: report of a case with special reference to 380 cases in the Japanese literature. Breast cancer (Tokyo, Japan) 2005; 12: 154-158
20 Jennings WC, Baker RS, Murray SS. et al. Primary breast lymphoma: the role of mastectomy and the importance of lymph node status. Annals of surgery 2007; 245: 784-789